Safety & Warnings

G6PD deficiency — and why it matters for methylene blue

What is G6PD deficiency?

Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in every red blood cell. Its job is to generate NADPH, which protects the cell from oxidative stress. Without enough G6PD, red blood cells can't defend themselves — certain drugs, foods (fava beans), and infections cause them to burst, a condition called acute hemolytic anemia.

G6PD deficiency is the most common inherited enzyme deficiency worldwide. It affects roughly 400 million people globally. It's X-linked, so it shows up more often in men, and is more common in people with ancestry from sub-Saharan Africa, the Mediterranean basin, the Middle East, India, and Southeast Asia. Many people with it have never had symptoms — until they take a drug that triggers hemolysis.

Why does this affect methylene blue?

Methylene blue is a strong reducer / oxidizer. In a person with normal G6PD, their red cells handle the oxidative load fine. In a person with G6PD deficiency, methylene blue can trigger severe acute hemolytic anemia — in rare cases, life-threatening.

This is why our intake asks about ancestry and family history of "reactions to fava beans or antimalarials," and why we order a simple G6PD activity assay before dispensing methylene blue to anyone in a higher-prevalence group or with any family history of hemolytic events.

Screening

A quantitative G6PD enzyme assay is a single blood draw, processed at a standard reference lab. If your result is normal, methylene blue is safe from that standpoint. If your result shows deficiency, we will not dispense methylene blue — and your provider will recommend alternative mitochondrial support (e.g., CoQ10, urolithin-A) that carries no G6PD risk.

Serotonin syndrome & MAO-A (methylene blue, separate from G6PD)

Methylene blue is also a potent MAO-A inhibitor at clinical doses. MAO-A breaks down serotonin in the body. If you combine a strong MAO-A inhibitor with a serotonergic drug — most commonly SSRIs (sertraline, escitalopram, fluoxetine, citalopram, paroxetine) or SNRIs (venlafaxine, duloxetine) — you can develop serotonin syndrome: agitation, high heart rate, fever, muscle rigidity, seizures. It can be fatal.

Because of this, our intake asks explicitly about current antidepressants and other serotonergic medications. If you're on any of the following, methylene blue is contraindicated and we'll prescribe alternatives:

• SSRIs, SNRIs, tricyclics, MAOIs
• Triptans (migraine drugs like sumatriptan)
• Tramadol, linezolid, dextromethorphan at high doses
• St. John's Wort
• Amphetamines or MDMA recreationally

Ancient pink-urine and temporary blue-green urine are normal and harmless. Serotonin-syndrome symptoms are not — if you experience tremor, agitation, fever, or rapid heart rate, stop methylene blue immediately and seek care.

iPLEDGE — required to dispense isotretinoin

What is iPLEDGE?

iPLEDGE is the FDA's Risk Evaluation and Mitigation Strategy (REMS) program for isotretinoin. It exists because isotretinoin is severely teratogenic: a single dose during early pregnancy can cause catastrophic birth defects affecting the brain, heart, face, ears, eyes, and thymus. No amount is safe during pregnancy. The program applies to every dose strength, including the 5 mg / 10 mg microdose protocols — there is no exemption.

What the drug actually does to a pregnancy

In pregnancies exposed to isotretinoin during weeks 3–8 of gestation (when the embryo's organs are forming), roughly one in three babies has a major congenital malformation. The pattern is consistent enough that it has its own name — retinoic-acid embryopathy. Typical features:

• Face and head: missing or malformed external ears (microtia / anotia), cleft palate, small lower jaw (micrognathia), high forehead.
• Brain and CNS: hydrocephaly, microcephaly, cerebellar malformation, intellectual disability.
• Heart: conotruncal defects (transposition of the great arteries, truncus arteriosus, tetralogy of Fallot), interrupted aortic arch.
• Thymus: thymic aplasia → permanent immunodeficiency.
• Eye: optic-nerve hypoplasia, microphthalmia.

Exposed pregnancies also carry much higher rates of spontaneous abortion and stillbirth. The biggest source of harm has historically been pregnancies that were already underway at the time of the first dose — i.e. the patient didn't know they were pregnant yet. Every layer of the iPLEDGE protocol is built to prevent exactly that.

What iPLEDGE requires — every patient

Every patient who receives isotretinoin in the U.S. — including through microdose protocols — must:

• Register in the iPLEDGE system (it's free; we handle the paperwork).
• Review the iPLEDGE educational materials and acknowledge the risks.
• Complete a monthly attestation before each refill is released by the pharmacy.
• Agree not to share, donate, or transfer any of your medication.
• Agree not to donate blood during treatment and for 1 month after stopping.
• Avoid vitamin-A supplements above 10,000 IU/day and tetracycline-class antibiotics for the duration of therapy.
• Monthly pickups only — you cannot stockpile isotretinoin.

NoTimeRx women's protocol — what's different and why

Isotretinoin has been available to women since the 1980s, and the women's protocol has gotten progressively stricter over four decades because every loosening of the rules has produced a spike in exposed pregnancies. The NoTimeRx women's protocol follows the current REMS requirements to the letter — no shortcuts. Women of childbearing potential (the iPLEDGE term is "patients of reproductive potential") go through every step on this list. The gap from intake to first prescription is typically 30–45 days for women vs. about 7 days for men. That gap is not arbitrary — it's the contraception lead-in window plus the two negative serum pregnancy tests separated by 30 days that the REMS requires.

• Two independent forms of contraception, used simultaneously. One primary (IUD, implant, combined oral contraceptive, progestin-only pill, ring, patch, injection, or surgical sterilization) plus one backup (usually condoms). True continuous abstinence counts as a method, but "occasional condom use" does not.
• Contraception starts at least 1 month BEFORE the first dose and continues for at least 1 month AFTER the last dose. This lead-in / washout window keeps the drug out of any pregnancy conceived near the start or end of therapy.
• Two negative serum βhCG pregnancy tests — one at intake and a second 30 days later — before the first prescription is released. Urine tests are not acceptable for the initial qualification under the REMS; serum is required.
• Monthly serum pregnancy testing for the entire duration of therapy. The pharmacy cannot release the next refill until the negative result is on file in iPLEDGE.
• Video consult with your prescriber before the first prescription is released. The provider walks through the risks, confirms your contraception plan is real and in place, and answers questions. This is not a 5-minute async review.
• Immediate pregnancy-report obligation. If a pregnancy is suspected or confirmed at any point during therapy or in the 1-month washout after, the drug is stopped that day and the provider notifies iPLEDGE. You will not be penalized for reporting; delayed or concealed reports are exactly what the REMS is designed to prevent.

Why this is stricter for women and not for men: isotretinoin in semen at microdose exposures is not thought to cause fetal effects, and men metabolize the drug through their own liver rather than through a developing placenta. The entire teratogenic risk sits on the pregnant person's side of the equation, which is also where the prevention protocol has to live. None of this is a judgement of anyone's sexual behavior — it's that a fraction of every population of sexually-active women experience unplanned pregnancies each year, and on isotretinoin that number must be zero.

Microdose isotretinoin — does iPLEDGE still apply?

Yes. The FDA requires iPLEDGE enrollment for any dose of isotretinoin, including the 5 mg and 10 mg protocols used for long-term sebum control and maintenance. The teratogenicity risk is not proportional to dose at the levels involved — even the microdose delivers enough systemic drug to cause embryopathy if a pregnancy is exposed. We handle enrollment and monthly check-ins; you still complete every pregnancy test, contraception attestation, and video consult the REMS requires.

Other isotretinoin cautions

• Dry skin, lips, and eyes. Keep Aquaphor and preservative-free artificial tears on hand.
• Elevated triglycerides and LFTs. We check baseline labs and repeat at months 1 and 3.
• Night vision changes. Usually reversible. Flag to your provider if it affects driving.
• Mood changes. The population-level association with depression is contested, but individual patients can be sensitive. Flag any mood change immediately.
• No blood donation during treatment and for 1 month after.

Finasteride & dutasteride (5α-reductase inhibitors)

Finasteride and dutasteride block the enzyme that converts testosterone into its more potent form, dihydrotestosterone (DHT). That's why they work for hair loss — and also why they have a specific side-effect profile.

• Sexual side effects — decreased libido, erectile or ejaculatory changes. Generally rare and reversible on discontinuation.
• Mood changes — low mood, anxiety, depression. Flag these and stop if meaningful.
• Cognitive changes — "post-finasteride syndrome" is a contested clinical entity. Some patients report persistent symptoms after discontinuation; population data do not consistently confirm causality.
• Breast tenderness / gynecomastia — rare, stop if it develops.
• PSA — 5-AR inhibitors can lower measured PSA by ~50%. If you're being monitored for prostate issues, tell your urologist you're taking one.
• Pregnancy risk — these drugs are teratogenic. Pregnant partners should not handle crushed/broken tablets.

If you've had any of these effects before, our intake asks explicitly and we route you through a separate non-hormonal pathway (valproate spray, apremilast foam) instead of reaching for 5-AR blockade again. If you choose to proceed anyway, you'll sign an informed-consent waiver.

Oral minoxidil

Low-dose oral minoxidil (typically 2.5–5 mg daily) is effective for diffuse thinning but has cardiovascular considerations. We screen for:

• Low blood pressure — can cause lightheadedness or orthostatic hypotension.
• Heart disease — high-dose minoxidil (40–100 mg) has historically been used for severe hypertension with significant cardiac effects; low doses are much safer but still require screening.
• Pericardial effusion — very rare at low doses.
• Edema / fluid retention — monitor for ankle swelling; dose-adjust if present.
• Unwanted body / facial hair growth — dose-dependent, reversible.

Low-dose naltrexone (LDN)

LDN at 1.5–4.5 mg (oral or intranasal) is well-tolerated but has specific interactions:

• Do not combine with opioid pain medicine. LDN blocks opioid receptors and will precipitate withdrawal or blunt analgesia.
• TSH and LFTs at baseline. LDN can modulate thyroid autoimmunity; we want a baseline before starting.
• Vivid dreams are common early and usually fade by week 2–3.
• Surgery planning — tell your surgical team you're on LDN so anesthesia planning accounts for opioid-receptor blockade.

Note: SLEEPMAXX no longer contains LDN — it was replaced with microdose doxepin (see below).

Doxepin — microdose (SLEEPMAXX)

What it is

Doxepin is an old tricyclic antidepressant. At its antidepressant doses (75–150 mg) it acts on multiple receptors and carries the typical TCA side-effect burden. At microdoses of 1–6 mg, almost all of those effects drop out and what's left is selective histamine H₁ antagonism — which is the receptor that gates sleep maintenance. The FDA approved doxepin at 3 mg and 6 mg (Silenor®) specifically for sleep-maintenance insomnia in 2010, and the SLEEPMAXX troche uses the same dose range.

Dosing on NoTimeRx

• Start: 1 mg. Always. We don't start anyone higher.
• Titrate to 3 mg if 1 mg is well-tolerated but undershooting.
• 6 mg is gated. Available only to patients who've been on doxepin on-platform for more than 6 months with documented benefit and clean monthly check-ins. Your provider activates the dose option in the rx-customize panel — it's not a self-serve bump.

Hard contraindications

• Active narrow-angle (closed-angle) glaucoma. Doxepin's mild anticholinergic activity can precipitate an acute angle-closure attack. If you've had laser iridotomy or your ophthalmologist says you're cleared, tell your provider.
• Urinary retention. BPH with significant retention, neurogenic bladder, post-op retention — all reasons to defer.
• Severe untreated obstructive sleep apnea. Sedating any patient with untreated OSA worsens hypoxic episodes. If you have OSA, get on CPAP / appliance therapy first; SLEEPMAXX is fine alongside an effective CPAP.
• MAOIs — or within 14 days of stopping one. Includes phenelzine, tranylcypromine, selegiline transdermal, methylene blue (which is a reversible MAO-A inhibitor), and linezolid. Serotonin syndrome / hypertensive crisis risk.

Cautions / disclose at intake

• Other anticholinergics. Stacking doxepin with diphenhydramine, doxylamine, oxybutynin, scopolamine, or first-generation antihistamines compounds dry mouth, constipation, blurred vision, and (more rarely) confusion in older adults.
• Other CNS depressants. Benzodiazepines, Z-drugs, opioids, and alcohol all add to the sedation. Alcohol on top of SLEEPMAXX is the highest-risk stack — don't.
• Strong CYP2D6 / CYP3A4 inhibitors (paroxetine, fluoxetine, bupropion, terbinafine; ketoconazole, clarithromycin, ritonavir) raise doxepin exposure. We adjust dose down or pick a different agent.
• QT-prolonging drugs at high TCA doses are a concern; at 1–6 mg the risk is minimal but we still avoid stacking with known QT prolongers (certain antiarrhythmics, methadone, ondansetron at high dose).

Pregnancy & breastfeeding

Doxepin crosses the placenta and is excreted in breast milk; even microdoses have not been studied in either context. SLEEPMAXX is not prescribed during pregnancy or breastfeeding.

Operating vehicles / heavy machinery

At 1–3 mg most people have no measurable next-morning impairment; at 6 mg some patients notice it. Allow at least 8 hours of sleep before driving, and the first week of any dose change, give yourself extra margin.

Addyi (flibanserin) — HSDD

What it treats

Addyi® is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It's not approved for postmenopausal HSDD, nor for low desire that's explained by another medical condition, a mental health condition, a relationship problem, or a drug side effect. Your provider screens for each of those at intake — if one of them fits, the right move is to treat that, not layer flibanserin on top.

How it works

Flibanserin is a 5-HT_1A agonist and 5-HT_2A antagonist that rebalances serotonin, dopamine, and norepinephrine in the brain circuits tied to sexual desire. It's not a hormone, not a PDE5 inhibitor, and not an aphrodisiac — it's a neurotransmitter modulator taken daily to nudge the set-point over time.

Dosing + timeline

• 100 mg orally once daily, at bedtime. Taking it earlier risks hypotension and somnolence during waking hours.
• Evaluate at 8 weeks. If you haven't seen meaningful benefit by week 8, we discontinue — continuing longer rarely helps.
• Effect size in RCTs is modest: ~0.5–1 additional satisfying sexual event per month versus placebo, plus reduced distress scores.

⚠️ Alcohol — absolute restriction

This is the biggest warning on the label. Combining any amount of alcohol with Addyi can cause severe hypotension (low blood pressure) and syncope (fainting). The FDA initially required complete abstinence; after additional study the label now acknowledges the risk is worst with heavy or acute use, but NoTimeRx's protocol is to ask you to abstain completely while on flibanserin. If you can't or don't want to, this drug is probably the wrong fit.

Drug interactions

• CYP3A4 inhibitors increase flibanserin levels dramatically — contraindicated with strong inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice).
• Moderate CYP3A4 inhibitors (fluconazole, diltiazem, erythromycin) require dose adjustment or alternative timing — your provider handles this.
• Hepatic impairment: contraindicated — skipped entirely if LFTs / a clinical liver-disease flag shows up.

Common side effects

Dizziness, sleepiness (so — bedtime), nausea, fatigue, insomnia, dry mouth. Most are dose-related and fade after the first 2–4 weeks. If you're fainting or feel near-fainting when standing up, stop and call us.

PDE5 inhibitors (sildenafil, tadalafil) — the hard rule

The cardinal contraindication: do not combine sildenafil or tadalafil with any nitrate medication. That includes nitroglycerin (tablets, spray, patches), isosorbide mononitrate/dinitrate, and recreational "poppers" (amyl/butyl nitrite). The combination can cause a catastrophic drop in blood pressure.

Other screening flags:

• Recent (within 6 months) heart attack, stroke, or life-threatening arrhythmia
• Uncontrolled high blood pressure or hypotension
• Severe hepatic impairment
• Hereditary retinal disorders (retinitis pigmentosa)
• Prior priapism (painful erection >4 hours)

Common manageable side effects: headache, flushing, nasal congestion, indigestion, visible-color changes (rare, sildenafil only), back pain / muscle aches (more common with tadalafil).

hCG — men's fertility & TRT adjunct

Human chorionic gonadotropin (hCG) binds the LH receptor on Leydig cells, driving intratesticular testosterone production. That's the specific signal spermatogenesis needs — which is why hCG is used either to restore fertility in men with secondary hypogonadism or to preserve fertility during testosterone replacement therapy (otherwise TRT shuts the testes down).

Before we prescribe

• Baseline labs: total T, free T, LH, FSH, E₂, SHBG, TSH, prolactin, HbA_1c.
• Semen analysis at a local Quest/LabCorp — we coordinate the order.
• Prostate screening: age-appropriate PSA. hCG-driven T rise can unmask or accelerate hormone-responsive prostate disease.
• Cardiovascular status review.

During treatment

• Typical dose: 1,500–3,000 IU subcutaneous, 2–3× per week
• Re-check labs + semen analysis at 3 months (full spermatogenesis cycle)
• Watch for: gynecomastia (if E₂ climbs — anastrozole may be added), acne, mood changes, injection-site reactions

Contraindications

• Known or suspected androgen-responsive tumor (prostate, male breast)
• Precocious puberty
• History of thromboembolic disease without hematology clearance

Clomiphene / Enclomiphene — SERMs for fertility

Clomiphene blocks estrogen feedback at the hypothalamus. Less feedback → more GnRH → more LH and FSH → more endogenous testosterone and more spermatogenesis (men) or a developing follicle (women). Enclomiphene is the pure trans-isomer of clomiphene — same mechanism, cleaner side-effect profile.

Men

• Enclomiphene 12.5–25 mg daily (or EOD); recheck labs at 6–8 weeks
• Preserves testicular size + fertility, unlike TRT
• Side effects: mild mood changes, blurred vision (rare; reversible)

Women

• Clomiphene 50 mg cycle days 5–9; escalate to 100 mg if no ovulation
• Maximum 3–6 cycles before re-evaluation
• Side effects: hot flashes, mood lability, ovarian cysts (reason for ultrasound before each new cycle when available), visual disturbances (stop if any)
• Multiple-pregnancy risk: ~8% twin rate on clomiphene — higher than natural ~1% baseline

Letrozole — ovulation induction

Aromatase inhibitor that lowers estrogen, which raises FSH and stimulates follicle growth. ASRM's 2018 first-line recommendation for PCOS-related anovulation (it outperforms clomiphene in live-birth rate in PCOS — Legro et al., NEJM 2014). Shorter half-life than clomiphene, which means thinner endometrial effects and lower twin rates.

• 2.5–5 mg orally on cycle days 3–7 (or 5–9)
• Requires ovulation confirmation — LH strips at home, or local transvaginal ultrasound
• Use-in-pregnancy is category X; we only prescribe for the follicular phase
• Side effects: hot flashes, fatigue, headache — transient

Fertility via telemedicine — what we can and can't do

NoTimeRx handles first-line fertility optimization. That covers:

• Semen analysis ordering + interpretation (at your local lab)
• Full reproductive hormone panel (T, LH, FSH, E₂, SHBG, AMH, TSH, prolactin)
• Prescribing hCG, enclomiphene, anastrozole, clomiphene, letrozole, metformin, micronized progesterone
• Quarterly follow-up labs and dose adjustment

We don't provide — and will refer you to a local reproductive endocrinologist (REI) for — any of:

• Intrauterine insemination (IUI) or in-vitro fertilization (IVF)
• Transvaginal ultrasound cycle monitoring or follicle tracking
• Egg retrieval, embryo transfer, frozen embryo cycles
• Surgical sperm extraction (TESA/TESE)
• Tubal patency evaluation (HSG), uterine imaging (saline sonography)
• Preimplantation genetic testing

If your workup points to any of those, your provider will say so directly, coordinate a handoff to an REI near you, and continue to handle whatever optimization is safe to do in parallel.

Spironolactone — women's antiandrogen

Spironolactone is a potassium-sparing diuretic originally approved for blood pressure and heart failure, but its off-label use in women for hormonal acne, hirsutism, and PCOS-associated hyperandrogenism is well-established. It works by blocking androgen receptors and mildly suppressing androgen synthesis.

• Typical dose: 50–200 mg orally daily, lab-titrated
• Baseline + 4-week potassium + creatinine check (it can cause hyperkalemia)
• Avoid combining with potassium supplements, ACE inhibitors, or ARBs without monitoring
• Contraception required — pregnancy category C (can feminize a male fetus)
• Not indicated for men (feminizing effects, gynecomastia risk)
• Common side effects: diuresis (especially first 2 weeks), breast tenderness, menstrual irregularity, fatigue

Semaglutide & GLP-1 receptor agonists — PCOS off-label use

Semaglutide (brand: Ozempic®, Wegovy®, Rybelsus®) is a once-weekly GLP-1 receptor agonist FDA-approved for type-2 diabetes and chronic weight management. Growing evidence shows meaningful benefit in PCOS — improved insulin sensitivity, weight, ovulatory regularity, and androgen levels — but PCOS is not an FDA-approved indication. Our provider prescribes off-label when clinically warranted, documents the rationale, and screens you carefully.

Why we microdose (0.25 mg weekly) for PCOS

0.25 mg weekly is the standard starting dose for any semaglutide protocol (Wegovy / Ozempic labels both begin here). For PCOS, many patients get the insulin- sensitizing benefit at this dose without needing to climb to weight-loss-target doses (1.0–2.4 mg). Lower dose = fewer GI side effects, lower cost, easier to sustain.

Absolute contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or actively trying to conceive (washout 2 months before conception)
• History of pancreatitis
• Severe gastroparesis or other significant GI motility disorder
• Active gallbladder disease

Common side effects

• Nausea (~20% at start, fades over 2–4 weeks)
• Bloating, constipation, or loose stools
• Reduced appetite / early satiety (often a desired effect)
• Fatigue in the first 2 weeks

Serious side effects — stop and call us

• Severe abdominal pain radiating to back (possible pancreatitis)
• Neck lump, hoarseness, trouble swallowing (possible thyroid mass)
• Severe dehydration / prolonged vomiting
• Signs of gallbladder attack (RUQ pain, fever)

Important interactions

• Slowed gastric emptying alters absorption of oral contraceptives — we coordinate timing and may recommend a backup method during titration
• Insulin and sulfonylureas — hypoglycemia risk; doses adjusted in parallel
• Any surgery/endoscopy under anesthesia — hold for ≥1 week before due to delayed gastric emptying (aspiration risk)

Compounded vs branded

FDA shortage status determines whether semaglutide is dispensed as a compounded preparation by a 503A/503B pharmacy or as the branded product. When branded is available, compounded use is legally restricted. Your provider picks the appropriate path based on the current FDA status and your insurance.

Metronidazole & boric acid — vaginal BV / yeast

Metronidazole 0.75% vaginal gel

CDC first-line for bacterial vaginosis. Nitroimidazole that targets anaerobes without wiping out lactobacilli.

• One applicator vaginally nightly × 5 nights
• Avoid alcohol during treatment + 48 hrs after — disulfiram-like reaction (flushing, nausea, tachycardia)
• May stain fabrics; wear a pad during treatment
• Not a cure for recurrent BV alone — pair with boric acid maintenance for that pattern

Boric acid 600 mg vaginal suppositories

Evidence-based for recurrent BV, mixed infections, and azole-resistant Candida glabrata.

• Vaginal use only. ORAL INGESTION IS TOXIC. Lock away from children.
• Not for use in pregnancy
• Common: mild watery discharge during use
• Stop and seek care if: fever, pelvic pain, or symptoms don't improve in 7 days

Metformin — off-label healthspan use

Metformin is FDA-approved for type-2 diabetes and has 60+ years of real-world safety. Observational data associate metformin use with lower all-cause mortality and delayed onset of age-related diseases — the reason it's the active drug in the ongoing TAME trial (Targeting Aging with Metformin), the first FDA-accepted clinical endpoint for aging itself.

Who we'll prescribe it to off-label

• Adults with metabolic inflexibility (fasting insulin high, HbA_1c borderline), PCOS, or clear healthspan goal
• eGFR ≥ 45 (dose-adjust between 30–45; avoid entirely below 30)
• No current heavy alcohol use, liver disease, heart failure decompensation

Dosing + monitoring

• Start 500 mg extended-release with dinner; titrate by 500 mg every 1–2 weeks to 1000–1500 mg as tolerated
• Use extended-release over immediate-release to reduce GI side effects
• Baseline labs: comprehensive metabolic, B₁₂, lipid panel, HbA_1c, TSH
• Repeat labs at 3 months then annually; B₁₂ monitoring because chronic metformin can lower it
• Hold the day before any scan with IV iodinated contrast — lactic-acidosis risk

Common side effects

GI upset (bloat, loose stool) is the big one — almost always dose-related and worse with immediate-release. Start low, titrate slow. Metallic taste, reduced B₁₂, and mild weight loss are common.

Flavone-based nootropics — Tropoflavin and analogs

Tropoflavin (7,8-DHF) and 4'-DMA-7,8-DHF are not approved for human consumption. We list them transparently — they're included because some patients specifically request them after reviewing the preclinical literature. Your intake asks about prescription medications (to check interactions) and your provider reviews for contraindications.

Supplements vs prescription drugs — the DSHEA framing

Everything on the Nootropics page plus several items in Longevity (Amorfrutins, Sperm Quality Stack, Vaginal probiotic, False Indigo) is a dietary supplement, not a prescription drug. Supplements are regulated in the U.S. under the Dietary Supplement Health and Education Act (DSHEA, 1994):

• Manufacturers are responsible for safety before marketing; the FDA doesn't pre-approve them.
• Supplements cannot claim to diagnose, treat, cure, or prevent disease — that language is reserved for drugs.
• Good Manufacturing Practices (21 CFR 111) apply, but enforcement quality varies. We source from GMP-certified manufacturers and third-party test every batch.
• Supplements can still interact with prescription drugs. Your intake lists current medications; your provider cross-checks before recommending additions.

If a supplement on our site looks weirdly "drug-like" in its description, that's because we try to tell you the real mechanism even when DSHEA limits how we can phrase the benefit. If it reads like hand-waving, it's because the evidence is still emerging — we'd rather say that out loud than pretend otherwise.

Compounded peptides — regulatory & clinical notes

BPC-157, TB-500, KPV, and similar peptides are not FDA-approved as finished drugs. They are compounded on a patient-specific basis by state-licensed compounding pharmacies and prescribed off-label. The FDA has, in recent years, placed several peptides on bulk-substance Category 2, which restricts which pharmacies can compound them and for which indications.

What this means for you:

• Your provider documents a clinical rationale for each prescription.
• We only work with pharmacies that maintain clean state and federal inspection records.
• We do not sell unregulated bulk peptide powders — what we dispense is compounded sterile/pharmaceutical-grade by state-licensed pharmacies.
• Long-term safety data is limited. Your provider will want periodic check-ins.

Topical retinoids (tretinoin, tazarotene)

• Photosensitivity. Use SPF 30+ daily. Apply retinoids only at night.
• The purge. Weeks 2–6 can worsen before they improve. Don't abandon early.
• Pregnancy. Topical retinoids are category C — not demonstrated safe in pregnancy. Stop if you become pregnant.
• Layering. Don't layer with benzoyl peroxide or AHAs on the same night unless your provider approves.
• Tazarotene is more potent than tretinoin at equal percentages — start with longer spacing (every third night) and work up.

Pregnancy & breastfeeding — universal rules

The following categories of our catalog are absolutely not for use during pregnancy (and mostly not while breastfeeding):

• Finasteride, dutasteride (any form) — teratogenic
• Isotretinoin (any dose) — severely teratogenic (iPLEDGE exists for this reason)
• Tretinoin, tazarotene (topical) — retinoid category
• Oral minoxidil — use only with obstetric guidance
• Methylene blue — class C, avoid except in medical emergencies

Safer during pregnancy with provider approval: nano-hydroxyapatite toothpaste, mild topical PEA cream, Ciclopirox shampoo (minimal systemic absorption). Ask every time.

When to call 911 instead of us

NoTimeRx is a non-urgent telemedicine service. If you experience any of the following, call 911 or go to the nearest emergency room immediately:

• Chest pain, shortness of breath, or signs of heart attack or stroke
• Severe allergic reaction (trouble breathing, swelling of face/throat, widespread hives)
• Signs of serotonin syndrome (high fever, agitation, muscle rigidity) while on methylene blue
• Dark / cola-colored urine, pallor, fatigue shortly after starting methylene blue (possible hemolysis)
• Suicidal ideation or self-harm thoughts — also reachable at 988 (U.S. Suicide & Crisis Lifeline)
• Severe abdominal pain or vomiting blood